Your email has been successfully added to our mailing list.

×
-0.00694444444444442 -0.00694444444444442 -0.0152777777777777 0.00555555555555556 0.0777777777777778 -0.145 -0.186111111111111 -0.160152777777778
Stock impact report

Tonix up big on start of late-stage study of TNX-102 SL; shares ahead 66% premarket [Seeking Alpha]

Tonix Pharmaceuticals Holding Corp. (TNXP) 
Last tonix pharmaceuticals holding corp. earnings: 3/24 05:15 pm Check Earnings Report
US:NASDAQ Investor Relations: tonixpharma.com
Company Research Source: Seeking Alpha
Investors are downright giddy over Tonix Pharmaceuticals' (NASDAQ: TNXP ) start of a Phase 3 clinical trial assessing TNX-102 SL in PTSD. Shares are up  premarket on robust volume. The study is expected to wind up in October 2018. Previously: Enrollment underway in Tonix Pharma's late-stage study of TNX-102 in PTSD (March 28) Now read: Tonix Pharmaceuticals (TNXP) Investor Presentation - Slideshow » Show less Read more
Impact Snapshot
Event Time:
TNXP
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last Price
VWAP
High:
Max Up
High:
Low:
Max Down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Opt-in for TNXP alerts
Opt-in for
TNXP alerts

from News Quantified
Opt-in for
TNXP alerts

from News Quantified